Vera Therapeutics, Inc. (VERA) — Financial statements
Income statement, balance sheet, and cash flow for Vera Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↑100.0% | -0.85 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00↓100.0% | 0.85 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 215↑70.6% | 126↑61.3% | 78↑12.0% | 70↑210.6% | 22 | |
| General & Administrative Expenses | 100↑144.4% | 41↑72.4% | 24 | 0.00↓100.0% | 12 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 100↑144.4% | 41↑72.4% | 24↑8.6% | 22↑83.8% | 12 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 315↑88.7% | 167↑63.9% | 102↑11.2% | 92↑166.7% | 34 | |
| Total Costs & Expenses | 315↑88.7% | 167↑63.9% | 102↑12.2% | 91↑164.2% | 34 | |
| Operating Results | ||||||
| Operating Income | -315↓88.7% | -167↓63.9% | -102↓12.2% | -91↓164.2% | -34 | |
| Depreciation & Amortization | 0.47↑345.7% | 0.11↑400.0% | 0.02↑102.5% | -0.85↓580.7% | 0.18 | |
| EBITDA | -292↓101.9% | -144↓56.7% | -92↓3.7% | -89↓174.3% | -32 | |
| EBIT | -292↓102.1% | -145↓56.7% | -92↓4.7% | -88↓170.2% | -33 | |
| Interest & Other Income | ||||||
| Net Interest Income | 17↑29.5% | 13↑212.1% | 4↑453.2% | 0.76↑15260.0% | -0.01 | |
| Interest Income | 24↑18.2% | 21↑159.6% | 8↑355.9% | 2↑11566.7% | 0.02 | |
| Interest Expense | 8↓1.2% | 8↑101.4% | 4↑281.7% | 0.99↑4860.0% | 0.02 | |
| Non-Operating Income | -23↓3.3% | -23↓130.9% | -10↓245.4% | -3↓56.6% | -2 | |
| Other Income / Expenses | 16↑5.6% | 15↑149.4% | 6↑225.9% | 2↑3.0% | 2 | |
| Income Before Tax | -300↓96.9% | -152↓58.5% | -96↓7.8% | -89↓173.1% | -33 | |
| Income Tax Expense | 0.00↑0.0% | 0.00↑0.0% | 0.00↑0.0% | 0.00↑0.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -300↓96.9% | -152↓58.5% | -96↓7.8% | -89↓173.1% | -33 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -300↓96.9% | -152↓58.5% | -96↓7.8% | -89↓173.1% | -33 | |
| Bottom-Line Net Income | -300↓96.9% | -152↓58.5% | -96↓7.8% | -89↓173.1% | -33 | |
| EPS (Basic) | -4.66↓69.5% | -2.75↓22.2% | -2.25↑32.8% | -3.35↓37.9% | -2.43 | |
| EPS (Diluted) | -4.66↓69.5% | -2.75↓22.2% | -2.25↑32.8% | -3.35↓37.9% | -2.43 | |
| Weighted Average Shares | 64↑16.1% | 55↑29.5% | 43↑60.7% | 27↑97.8% | 13 | |
| Weighted Average Diluted Shares | 64↑16.1% | 55↑29.5% | 43↑60.7% | 27↑97.8% | 13 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.